Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC

Inclusion Criteria: * Histologically or cytologically-confirmed metastatic pancreatic ductal adenocarcinoma. * Availability of a tumor tissue specimen. If no archived tumor tissue is available, then a de novo biopsy is required for patient participation. * Karnofsky Performance Status 70 or greater. * Adequate Bone Marrow, Renal, and Liver Function. Exclusion Criteria: * Prior treatment with a CDK 4/6 inhibitor. * Prior treatment with nab-P for the treatment of metastatic disease. * Patients with known CNS metastases, carcinomatous meningitis, or leptomeningeal disease as indicated by clinical symptoms, cerebral edema, and/or progressive growth. * Diagnosis of any other malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix. * QTc \>480 msec, or family or personal history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes. * Uncontrolled electrolyte disorders. * Cardiac or pulmonary disorders within 6 months of enrollment. * Known human immunodeficiency virus infection. * History of interstitial lung disease or pneumonitis. * Other severe acute or chronic medical or psychiatric condition that may increase the risk associated with study participation. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to nab-P. * Difficulty swallowing capsules or requirement for a feeding tu…